Pilot Trial: Venetoclax (BCL2 inhibitor) in pediatric AML chemotherapy substitution

Investigators aim to assess whether substituting two cycles of intensive chemotherapy (Ida-FLA and VIA) for standard regimens in intermediate and high risk pediatric AML patients yields comparable or improved survival while reducing long-term complications. The study enrolls children following their first induction cycle in Houston under Joanna Yi’s oversight and evaluates tolerability and outcomes over three years, with venetoclax (a BCL2 inhibitor), idarubicin (a DNA synthesis inhibitor), and fludarabine (a DNA synthesis inhibitor) as key investigational agents in this pilot trial.